Orgaran (Danaparoid Sodium)

Danaparoid sodium enhances the activity of antithrombin III and heparin cofactor II, selectively inhibiting factor Xa. This inhibition reduces thrombin generation, limiting fibrin clot formation and providing effective anticoagulation while sparing other coagulation pathways.

The prescribed dose of Orgaran is determined by the treating physician based on the specific indication, patient weight, renal function, and individual bleeding risk. Dosing follows the approved label and clinical guidelines, and should not be altered without medical supervision.

Safety data for danaparoid sodium during pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To order Orgaran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Compared with unfractionated heparin, danaparoid has a lower incidence of heparin‑induced thrombocytopenia and offers more predictable anti‑Xa activity, though it requires intravenous administration and careful monitoring. Relative to low‑molecular‑weight heparins, it provides similar efficacy with distinct pharmacokinetic properties and a different safety profile.

Orgaran must be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Vials should remain in their original packaging until use, and any unused portion should be discarded according to local regulations and pharmacy best practices.

Orgaran is supplied as a sterile solution for intravenous injection. Administration is performed by a qualified healthcare professional, typically as a slow bolus or continuous infusion, depending on the clinical protocol and indication, using aseptic technique and appropriate venous access.

The most serious risks include severe or uncontrolled bleeding, adrenal hemorrhage, hypersensitivity reactions such as anaphylaxis, and rare thrombotic complications. Patients should be closely monitored for signs of bleeding, sudden hypotension, or allergic symptoms, and therapy should be discontinued if serious adverse events occur.

Orgaran is contraindicated in patients with active major bleeding, known hypersensitivity to danaparoid or any formulation component, severe uncontrolled hypertension, and those at high risk of bleeding where anticoagulation is not justified. Caution is also advised for individuals with severe renal impairment or those receiving other potent anticoagulants.